Article

Antibody Blockade of CCL25/CCR9 Ameliorates Early but not Late Chronic Murine Ileitis

Digestive Health Center of Excellence, Department of Internal Medicine, University of Virginia, Charlottesville, Virginia, USA.
Gastroenterology (Impact Factor: 13.93). 12/2006; 131(5):1518-29. DOI: 10.1053/j.gastro.2006.08.031
Source: PubMed

ABSTRACT CCL25 mediates the homeostatic recruitment of CCR9-expressing lymphocytes to the small intestine, but the function of this chemokine/receptor pair during chronic small intestinal inflammation has yet to be determined. Furthermore, although clinical trials to evaluate the efficacy of targeting the CCL25/CCR9 axis for the treatment of Crohn's disease are being conducted, preclinical data in animal models of IBD are lacking.
In the current studies, we investigated the expression of CCL25 and CCR9 as a function of disease progression in a spontaneous murine model of chronic ileitis (SAMP1/YitFc) using flow cytometry, real-time reverse-transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemistry. In addition, we assessed the functional role of the axis in the overall disease process through therapeutic studies that target the chemokine or the receptor during early and late disease.
The percentage of CCR9-expressing lymphocytes increased during early disease, accompanied by the appearance of a population of CCR9(high) lymphocytes, predominantly within CD8(+) T cells. Yet different from patients with primary sclerosing cholangitis, the expression of CCL25 remained restricted to the small intestine, even in mice with inflammation of the biliary tree. Neutralization of the receptor or the chemokine attenuated early disease but showed no therapeutic efficacy during the later stages, when overall CCR9 expression decreased and the CCR9(high) population was absent.
Our studies show that the role of this chemokine axis is not limited to homeostatic recruitment, as previously believed. However, these molecules appear to play their most crucial role during the early stages of chronic murine ileitis.

Download full-text

Full-text

Available from: Klaus Ley, Aug 12, 2015
0 Followers
 · 
245 Views
  • Source
    • "However, accumulating evidences showed that the CCR9/ CCL25 axis participated in a variety of disease processes (Johnson-Holiday et al. 2011; Nakamoto et al. 2012; Schmutz et al. 2010). In Crohn's disease patients (M et al. 2007) and in a murine model (Apostolaki et al. 2008; Rivera-Nieves et al. 2006), CCL25 was up-regulated following accumulation of CCR9 ? CD4 ? "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chemokines, by virtue of their ability to recruit immune cells into allografts, play critical roles in acute transplantation rejection. CCR9 and its ligand, CCL25, is one of the key regulators of thymocyte migration and maturation in normal and inflammatory conditions. Moreover, several studies have revealed that high expression of CCR9 and CCL25 participated in many kinds of diseases. However, the role of CCR9 in allograft rejection is still unclear. In this study, we established a murine skin transplantation model of acute rejection. Our findings showed that the proportion of CCR9-expressing T cells was significantly increased in the spleen of allotransplanted mice compared with syngeneic transplantation. Furthermore, expression of CCL25 in allograft was similarly increased. Neutralization of CCL25 by intravenous injection of anti-CCL25 monoclonal antibody significantly prolonged skin allograft survival, decreased the number of infiltrating cells, and simultaneously suppressed the chemotactic ability and the proliferation of the splenic T cells in response to allogeneic antigens. Finally, blockade of CCL25 also diminished the secretion of IFN-γ by splenic T cells. These studies indicated that CCR9/CCL25 was involved in acute transplantation rejection and anti-CCL25 strategies might be useful in preventing acute rejection.
    Archivum Immunologiae et Therapiae Experimentalis 03/2013; 61(3). DOI:10.1007/s00005-013-0223-4 · 2.82 Impact Factor
  • Source
    • "Another example is CCR9, expressed on intraepithelial and lamina propria T cells. CCR9 is involved in intestinal infiltration in IBD [45], probably by responding to CCL25, expressed by epithelial cells, specifically in the small intestine [46]. Results from a phase II clinical trial using a CCR9 antagonist in CD patients resulted in reduced disease severity [47]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Directional movement of cells in the human body is orchestrated via chemokines. This migration was initially identified in pathological and immunological processes but quickly extended to homeostatic cell trafficking. One such chemokine is the ubiquitous CXCL12 (initially called SDF1-α) which signals via the chemokine receptors CXCR4 and CXCR7. In the last decade CXCL12 was recognized to participate not only in embryonic development and homeostatic maintenance, but also in progression of inflammation. A role for CXCL12 and its receptors CXCR4 and CXCR7 in inflammatory bowel diseases was recently shown. The current review discusses up to date knowledge of CXCL12 in inflammation, focusing on the involvement of CXCL12 and its receptors, CXCR4 and CXCR7, in inflammatory bowel diseases.
    Theranostics 01/2013; 3(1):40-6. DOI:10.7150/thno.5135 · 7.83 Impact Factor
  • Source
    • "The ligand of this chemokine receptor, CCL25, is abundant in the SI but not the colon [5]. Furthermore, up-regulation of CCL25 in the inflamed SI following accumulation of CCR9 + CD4 + T cells has been reported in CD [6] and in a murine model [7]. Clinical trials involving an anti-CCR9 antagonist against CD are ongoing. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Almost all mice lacking specific molecules associated with regulatory T cells or barrier function develop intestinal inflammation in the colon, but not in the small intestine (SI). Therefore, intestinal homeostasis of the SI may be tightly controlled by other mechanisms. To determine the role of CCR9(+) plasmacytoid dendritic cells (pDCs) in intestinal homeostasis of the SI we transferred CD4(+)CD45RB(high) T cells into ccr9(-/-)×rag-2(-/-) mice. We showed that CCL25, a counterpart chemokine for CCR9, is constitutively expressed in the SI but not the colon and spleen of rag-2(-/-) or ccr9(-/-)×rag-2(-/-) mice before or after transfer of CD4(+)CD45RB(high) T cells. The ccr9(-/-)×rag-2(-/-) mice did not develop spontaneous intestinal inflammation in the SI and colon. Mice of both genotype where CD4(+)CD45RB(high) T cells were transferred developed colitis. However, the ccr9(-/-)×rag-2(-/-) mice also developed ileitis with marked infiltration of Th1 cells. These results suggest that CCR9(+) pDCs are possibly small, regulatory, antigen-presenting cells of the intestine that suppress intestinal inflammation.
    Immunology letters 05/2012; 146(1-2):64-9. DOI:10.1016/j.imlet.2012.05.001 · 2.37 Impact Factor
Show more